Thursday, March 19, 2026 3/19/2026

Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors

Award Number: R01CA271604
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2023
PERIOD OF PERFORMANCE END DATE: 12/31/2027

Group Awards By:

View Award Description

Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors - The overall goal of this proposal is to identify optimal strategies for primary prevention of cardiovascular disease (CVD) for survivors of breast (BC), prostate (PC) and lung (LC) cancer. All together, there are >6 million BC, PC and LC survivors in the US. While cancer is a major source of morbidity and mortality, the majority of BC and PC as well as many early-stage LC survivors die of comorbidities, particularly CVD. Cancer survivors have increased rates of both CVD risk factors as well as CVD itself, and CVD is the leading cause of death among BC and PC survivors. Among LC survivors, CVD-related deaths account for ~30% of mortality; this proportion is higher among the growing number identified with early-stage LC. In the general population, primary prevention with lipid-lowering agents (i.e., statins) and aspirin is highly effective for decreasing CVD incidence and mortality, but these guidelines for primary CVD prevention cannot be extrapolated to cancer survivors. Approaches for CVD prevention in cancer survivors need to consider traditional risk factors (including genetic risks) for CVD as well as CVD risk from certain cancer treatments. Additionally, competing risks from cancer recurrence or comorbidities may limit the long-term benefits of primary CVD prevention. Finally, the cancer itself, cancer treatment-related complications, and a higher prevalence of comorbidities can negatively impact quality-of-life and attenuate the absolute improvement in quality-adjusted life expectancy and the cost effectiveness (CE) of primary CVD prevention. Lack of specific data applicable to cancer survivors has profound negative impact, resulting in worse cardiovascular outcomes. It is unlikely that randomized controlled trials (RCT) assessing the benefits of CVD preventive strategies for cancer survivors will be ever conducted. Thus, there is an urgent need to use alternative methods to optimize preventive care recommendations for this growing population. We propose using simulation modeling, an approach complementary to clinical trials, to assess the harms, benefits, and CE of CVD prevention in a representative population of cancer survivors.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $628,625 )
2026	2026	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Cause and Prevention Research	000	4	2/19/2026	NON-COMPETING CONTINUATION	$628,625
														Subtotal = $628,625

Issue Date FY: 2025 ( Subtotal = $697,894 )
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Cause and Prevention Research	000	3	3/4/2025	NON-COMPETING CONTINUATION	$628,104
2025	2025	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Cause and Prevention Research	001	3	5/22/2025	NON-COMPETING CONTINUATION	$69,790
														Subtotal = $697,894

Issue Date FY: 2024 ( Subtotal = $663,802 )
2024	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Cause and Prevention Research	000	2	12/6/2023	NON-COMPETING CONTINUATION	$628,865
2024	2024	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	1 GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Cause and Prevention Research	001	2	4/16/2024	NON-COMPETING CONTINUATION	$34,937
														Subtotal = $663,802

Issue Date FY: 2023 ( Subtotal = $712,969 )
2023	2023	ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	ONE GUSTAVE L LEVY PL	NEW YORK	NY	10029	NEW YORK	USA	Cancer Cause and Prevention Research	000	1	12/9/2022	NEW	$712,969
														Subtotal = $712,969

Grand Total All Awards = $2,703,290

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modeling Best Approaches for Cardiovascular Disease Prevention in Cancer Survivors

Award Number: R01CA271604

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2023

PERIOD OF PERFORMANCE END DATE: 12/31/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer